Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama

Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama

Environmental surveillance was recommended for risk mitigation in a novel oral polio vaccine-2 (nOPV2) clinical trial (M5-ABMG) to monitor excretion, potential circulation, and loss of attenuation of the two nOPV2 candidates. The nOPV2 candidates were developed to address the risk of poliovirus (PV)...

Full description

Bibliographic Details
Main Authors: Magda Rojas-Bonilla, Angela Coulliette-Salmond, Hanen Belgasmi, Kimberly Wong, Leanna Sayyad, Everardo Vega, Fabian Grimoldi, M. Steven Oberste, Ricardo Rüttimann
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Viruses
Subjects:
polio
poliovirus
novel OPV2
environmental surveillance
Online Access:https://www.mdpi.com/1999-4915/13/7/1355

Similar Items

Similar Items